Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CRN Asks FDA To Stop Enforcement Against Synthetic Botanicals

This article was originally published in The Tan Sheet

Executive Summary

FDA’s position “is neither scientifically justified, logical nor in the interest of the public health,” CRN argues, asking FDA to reverse its position on synthetic botanicals outside the agency’s revision of the NDI draft guidance.

Advertisement

Related Content

FDA Enforces New Dietary Ingredient Notification Requirement With Import Alerts
FDA Enforces New Dietary Ingredient Notification Requirement With Import Alerts
FDA Enforces New Dietary Ingredient Notification Requirement With Import Alerts
FDA Enforces New Dietary Ingredient Notification Requirement With Import Alerts
DMAA Warnings Shed Light On FDA NDI Enforcement
Hatch, Harkin Call For Withdrawal of NDI Draft Guidance

Topics

Advertisement
UsernamePublicRestriction

Register

PS106046

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel